【活动】BioSpark聊biotech news：2024年七月生物医药大事讨论

汇聚群英智慧，闪亮你我星光

Together, Spark Biomedicine!

各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。

本月热点

TOPICS

1.  Oncology & Autoimmune Diseases：

• Roche discontinued two phase 3 NSCLC studies with anti-TIGIT after negative results from SKYSCRAPER-06;
• BioNTech & Regeneron reported positive phase 2 results for neoantigen vaccine BNT111 plus Libtayo in patients with R/R unresectable advanced melanoma;
• Revolution Medicines’ RAS(ON) multi-selective inhibitor RMC-6236 solidifies phase 3 plans with favorable safety profile and promising PFS data from a phase 1 trial of KRAS G12X PDAC patients; 
• Eli Lilly acquired Morphic Therapeutic for $3.2B, focusing on oral integrin α4β7 inhibitor for inflammatory bowel disease;
• Allogeneic CD19-targeted CAR-T for patients with severe myositis and systemic sclerosis;

2.  New Modalities:

• Hengrui’s 2nd HER2-ADC entered ph2;

• Orum Therapeutics and Vertex signed collaboration agreement to develop novel Degrader-Antibody Conjugates (DACs); 

• Dren Bio entered collaboration with Novartis to develop targeted myeloid engagers;

• Belief Biomed’s AAV-based Hemophila B gene therapy submitted its NDA;

• Reflections on Sarepta’s and Pfizer’s AAV gene therapies for Duchenne muscular dystrophy;

• Arrowhead Pharmaceuticals reported positive phase 3 topline results for Plozasiran in patients with familial chylomicronemia syndrome;

• Updates in Oligonucleotide field by Qinghong;

3.  Other Diseases & Business News:

• Roche’s $2.7B acquisition of Carmot Therapeutics delivered an oral GLP-1 with strong phase 1 obesity trial results;
• Viking Therapeutics’ dual GLP-1 / GIP receptor agonist VK2735 is expected to start Phase 3 trials;
• Venture capital dollars poured into biopharma in 2Q 2024.

活动详情

主题：Monthly biotech news discussion -July 2024 in review

时间：2024年08月03日 Sat 9:00 PM（EST）/ 2024年08月04日 周日 早上9:00 AM（北京时间）

地点：zoom meeting（扫描二维码获得zoom注册链接或点击文末“阅读原文”）

嘉宾：

Wenjun Wu (Armstrong,吴文君), Director @ HanKang Venture

(https://www.linkedin.com/in/文君-吴-14787b95/)

Stephen Yan (严顺飞), BD Search & Evaluation @ AstraZeneca 

(https://www.linkedin.com/in/shunfei-yan/)

Yanran He (何嫣然), Investment Director @ Sinopharm-CICC

(https://www.linkedin.cn/injobs/in/yanranhe)

Qinghong Yan (晏庆红), CSO @ Leverna Therapeutics 

(http://linkedin.com/in/qinghong-yan)

Leon 'Jun' TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory

(https://www.linkedin.com/in/leontangnyc/)

Lihua Yu (于利华), Chief Data Officer @ fogpharma 

(https://www.linkedin.com/in/lihua-yu-5b3337)

Yongjiang Hei (黑永疆),  Co-CEO @ Biocity Biopharma

( http://linkedin.com/in/yonghei)

Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc. (http://linkedin.com/in/charlene-liao-a1872a55)

Ethan Xu (徐亦迅), VP of Bioinformatics @ Aspen Neuroscience

(http://linkedin.com/in/ethan-yixun-xu-2b915a4)

Jimmy Wang (王俊), Assistant Professor @ New York University

(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)

本期活动组织：Ethan Xu & Qinghong Yan

本月热点总结：Armstrong和monthly news嘉宾

活动直播伙伴

About us

BioSpark

BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.

Follow us on Twitter: 
https://twitter.com/BioSpark_Group

Follow us on LinkedIn: 
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar: 
https://tinyurl.com/tcwy44t6

Email us: [e-mail]

合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group

 赞 助  机   构 

 战 略  合   作 

BioSpark Group致力于建立华人在生物医领域的生态系统和互助网络，立足于波士顿，我们在硅谷和中国与LEAP Initiative、Dahshu和医药笔记达成战略合作。

更多精彩，请关注BioSpark公众号